The Bull Case For Bicara Therapeutics (BCAX) Could Change Following Dual Inclusion In Major Biotech Indices [Yahoo! Finance]
Bicara Therapeutics (NASDAQ:BCAX) was upgraded by analysts at Mizuho to a "hold" rating.
Bicara Therapeutics (NASDAQ:BCAX) was given a new $18.00 price target on by analysts at Mizuho.
Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12
Bicara Therapeutics’ Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track for First Quarter 2026